FRYL Activators
FRYL Activators encompass a range of compounds that, through the inhibition of various kinases and signaling pathways, allow for the indirect enhancement of FRYL's functional activity within the cell. For instance, Bisindolylmaleimide I inhibits PKC, which can lead to elevated FRYL activity by minimizing PKC-mediated phosphorylation of competing targets, thus enabling FRYL to establish more robust interactions within its signaling complexes. Similarly, Y-27632's inhibition of ROCK influences the actin cytoskeleton, a cellular framework that is crucial for FRYL's roles in regulating cell interactions with FRYL. This broad inhibition of kinases can result in a less competitive environment for FRYL, allowing it to more effectively participate in its native signaling pathways related to cellular stress response, apoptosis, and cell cycle regulation.
Each compound listed operates through a unique mechanism, influencing different facets of cellular signaling and indirectly affecting FRYL activity. For example, Forskolin and IBMX operate by increasing the levels of cyclic nucleotides, which are second messengers in numerous signaling pathways, including those involving FRYL. These compounds, by elevating cAMP or inhibiting its degradation, respectively, can enhance the cellular conditions favorable for FRYL activity, leading to altered cellular responses. Similarly, compounds like PMA and A23187 exert their effects by activating PKC and increasing intracellular calcium levels, which can also modify FRYL's action in various pathways.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
Bisindolylmaleimide I is a specific inhibitor of protein kinase C (PKC), which indirectly can enhance FRYL activity by reducing PKC-mediated inhibitory phosphorylation of downstream targets that may compete with FRYL for binding partners or substrates. This allows FRYL to have increased interactions with its associated signaling complexes. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a selective inhibitor of ROCK (Rho-associated, coiled-coil containing protein kinase), which indirectly enhances FRYL activity by reducing the phosphorylation of actin cytoskeletal targets. This modulation of the cytoskeleton can create a cellular environment conducive to FRYL’s involvement in cell polarity and migration processes. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that, by reducing AKT phosphorylation, can indirectly enhance FRYL activity through modulating the PI3K/AKT pathway, which may regulate proteins that interact with FRYL, leading to enhanced FRYL-mediated signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor that can indirectly enhance FRYL activity by modulating AP-1 transcription factor activity, which could alter the expression of genes that encode proteins interacting with FRYL, thereby modifying FRYL signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that can indirectly enhance FRYL activity by modulating the cellular stress response, which could alter the phosphorylation state or availability of FRYL interaction partners within the stress response pathways. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor that can indirectly enhance FRYL activity by affecting the PI3K/AKT pathway, potentially changing the phosphorylation state or availability of substrates and binding partners that interact with FRYL. | ||||||
Gö 6976 | 136194-77-9 | sc-221684 | 500 µg | $223.00 | 8 | |
Gö6976 is a selective PKC inhibitor that can enhance FRYL activity by reducing PKC-mediated phosphorylation of proteins that may negatively regulate FRYL's interactions with its substrates or binding partners, thereby enhancing FRYL's signaling capacity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a SRC family kinase inhibitor that can indirectly enhance FRYL activity by reducing competitive phosphorylation events within signaling complexes, potentially allowing FRYL more access to its targets in signaling pathways where SRC kinases are active. | ||||||
SL-327 | 305350-87-2 | sc-200685 sc-200685A | 1 mg 10 mg | $107.00 $332.00 | 7 | |
SL327 is an inhibitor of MEK1/2, which can indirectly enhance FRYL function by reducing the activity of the downstream ERK pathway, potentially permitting greater FRYL activity in overlapping signaling pathways due to reduced phosphorylation of shared substrates or binding partners. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a specific MEK inhibitor that can enhance FRYL activity by reducing the phosphorylation of ERK, potentially increasing the availability of binding partners or substrates for FRYL in signaling pathways that are influenced by the MAPK/ERK pathway. | ||||||